2023-505601-16-00招募中3 期
C4951013 - AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Pfizer Inc.
- 入组人数
- 80
- 试验地点
- 47
- 主要终点
- Mean change from the observation phase (OP) in the number of migraine days per month over the entire double-blind treatment (DBT) Phase (Weeks 1 to 12).
研究概览
简要总结
To compare the efficacy of rimegepant to placebo as a preventive treatment for migraine in adolescents with chronic migraine.
研究设计
- 分配方式
- Na
- 主要目的
- Overall design OLE Phase
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 否
入选标准
- •Age and Sex:
- •Participants aged 12 to <18 years at the time of signing assent/consent. Participants must not reach their 18th birthday on or before the Randomization (Baseline) visit. • For EU countries and India ONLY: Participants must weigh greater than 40 kg
- •Disease Characteristics:
- •Participant has at least a 6-month history of migraine (with or without aura) consistent with a Diagnosis according to the International Classification of Headache Disorders, 3rd Edition1 including the following: • 15 or more headache days per month during the 3-month period prior to the Screening Visit. • 8 or more migraine days per month during the 3-month period prior to the Screening Visit. • 15 or more headache days during the OP. • 8 or more migraine days during the OP. • Ability to verbally distinguish migraine attacks from tension/cluster or other types of headaches. • Migraine attacks, on average, lasting 4 to 72 hours if untreated.
- •Other Inclusion Criteria:
- •Signed Written Informed Consent: • The participant is able to understand the Informed Assent Document (IAD) and the participant’s parent(s)/legal representative(s) (according to local regulations) are/is able to read and understand the Informed Consent Document (ICD). • The participant has signed the IAD/ICD (according to local regulations) and the participant’s parent(s)/legal representative(s) have/has signed the ICD prior to the conduct of any study-specific procedures. • The participant must be able to read and comprehend written instructions and be willing to complete all questionnaires under supervision of legal representative(s) as required by the protocol.
排除标准
- •Target Disease Exclusion: • Continuous migraine (defined as an unrelenting headache) within 1 month prior to Screening Visit. • Atypical migraine types, complications of a migraine, or a confounding and clinically significant pain syndrome that may interfere with the participant’s ability to participate in this study as assessed by the principal investigator (PI).
- •The following laboratory/electrocardiogram (ECG) values are exclusionary during the screening period: • Estimated glomerular filtration rate (eGFR)/creatinine clearance (CrCl) <45 mL/min/1.73m
- •Serum total bilirubin > upper limit of normal (ULN) (unless participant has known or suspected Gilbert’s Syndrome). • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x ULN (AST and/or ALT may be repeated once during the Screening period for assessment of eligibility). • An abnormal ECG at the screening visit that is clinically significant based on the investigator’s evaluation of the central reader’s interpretation. Determinations of eligibility based on QT interval will be based on the Fridericia correction where QTcF= QT/(RR⁰.³³).
- •Any medical condition or laboratory abnormality, including any clinically significant out-of-range vital signs, that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study (see Exclusion #10 for key parameters assessments for liver and renal function, and for cardiac evaluation).
- •Any current psychiatric condition that is uncontrolled and/or untreated.
- •Any “yes” response on the C-SSRS for the period of 30 days prior to Screening.
- •History of alcohol abuse and/or illicit drug use meeting DSM-5®² criteria for substance use disorder within 6 months of screening (excluding nicotine and caffeine). • Positive at screening for drugs of abuse, and who are on a prescribed medication for an approved indication (eg, ADHD), will be allowed into the study at the investigator’s discretion. This determination by the investigator must be well documented in the source medical records. The stimulant dose must be stable from 3 months prior to baseline until the end of treatment visit occurs.
- •History of severe drug allergy (such as anaphylaxis, or known hypersensitivity or intolerance to rimegepant or its excipients).
- •Current use of any prohibited concomitant medication(s).
- •More than 1 medication taken for migraine prevention/prophylaxis. • Concomitant use of a CGRP receptor antagonist, such as Nurtec™ or others, monoclonal antibodies such as erenumab, fremanezumab, or others <6 months prior to the Screening Visit. • Prophylactic migraine medication discontinued less than 30 days prior to the Screening Visit. • Prophylactic migraine medication not being stable for at least 3 months (12 weeks) prior to the OP, or dose expected to change during the course of the study.
- •Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products at any time during participation in this study is also exclusionary.
研究组 & 干预措施
RIMEGEPANT SULFATE
Test
干预措施: RIMEGEPANT SULFATE (Drug)
Placebo to rimegepant sulfate
Placebo
干预措施: Placebo to rimegepant sulfate (Drug)
结局指标
主要结局
Mean change from the observation phase (OP) in the number of migraine days per month over the entire double-blind treatment (DBT) Phase (Weeks 1 to 12).
Mean change from the observation phase (OP) in the number of migraine days per month over the entire double-blind treatment (DBT) Phase (Weeks 1 to 12).
次要结局
- Mean change from the OP in the number of acute migraine-specific medication days per month over the entire DBT Phase (Weeks 1 to 12).
- Mean change from the OP in the number of moderate or severe headache days per month over the entire DBT Phase (Weeks 1 to 12).
- Percentage of participants with ≥50% reduction from the OP in the number of moderate or severe migraine days per month over the entire DBT Phase (Weeks 1 to 12).
- Mean change from baseline in the PedsQL™ 4.0 Generic Core Scales total score at Week 12 of the DBT Phase.
- Mean change from the OP in the number of acute headache medication days per month and acute migraine-specific medicationdays per month in each month and over the entire DBT Phase.
- The number and percentage of participants with adverse events (AEs), serious adverse events (SAEs), AEs leading to study intervention discontinuation and grade 3 to 4 laboratory test abnormalities on treatment during the DBT and open-label extension (OLE) Phases.
- The number and percentage of participants with hepatic-relate AEs and hepatic-related AEs leading to study intervention discontinuation on treatment during the DBT and OLE Phases.
- Mean change from baseline in the PedMIDAS total score at Week 12 of the DBT Phase.
研究者
Clinical Medical Lead
Scientific
Pfizer Inc.
研究点 (47)
Loading locations...
相似试验
招募中
3 期
A Study to Learn About the Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Children and Adolescents.2024-512743-23-00Pfizer Inc.155
进行中（未招募）
3 期
一项在慢性偏头痛青少年患者中评价研究药物 Rimegepant 的研究CTR2025164115
招募中
3 期
Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With MigraineMigraine2022-501099-24-00Abbvie Deutschland GmbH & Co. KG, Abbvie Deutschland GmbH & Co. KG83
招募中
2 期
A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraineMigraine2024-512904-21-00AstraZeneca AB465
招募中
不适用
MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducation for Adolescents With MigrainePediatric MigraineMigraineNCT07419607Medical University Innsbruck30